Intelgenx Technologies Corp. | 10-Q: Quarterly report
IntelGenx Announces Voting Results on Election of Directors
IntelGenx Announces First Parkinson's Disease Patients Dosed With Montelukast VersaFilm in Phase 2 'MONTPARK' Clinical Trial
SAINT LAURENT, Quebec, April 08, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that Montelukast VersaFilm has been administered to
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
SAINT LAURENT, Quebec, April 05, 2024 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that its co-developer, Chemo Research SL, through its agent and affiliate,
IntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call Transcript
Earnings Call Summary | Intelgenx Technologies Corp.(IGXT.US) Q4 2023 Earnings Conference
The following is a summary of the IntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call Transcript:Financial Performance:IntelGenx reported Q4 total revenue of $426,000, a 146% increase compared t
IntelGenx GAAP EPS of -$0.01, Revenue of $0.43M
IntelGenx Technologies 4Q Rev $426,000 >IGX.T
IntelGenx Technologies 4Q Rev $426,000 >IGX.T
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
SAINT LAURENT, Quebec, March 21, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the three- and
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 - Conference Call to Follow
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow
SAINT LAURENT, Quebec, March 14, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) ("IntelGenx"), a leader in pharmaceutical films, today announced that it will release its fourth quarter and
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With Atai Life Sciences
SAINT LAURENT, Quebec, March 11, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company") announces that its wholly-owned subsidiary, IntelGenx Corp. ("IntelGenx Corp."), has entered
IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million Shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share, at an Offering Price of $10.00 Each, For a Max Offering Amount of $20 Million
07:52 AM EST, 02/20/2024 (MT Newswires) -- IntelGenx Brief: Launching Regulation A Offering of Up to 2 Million shares In Series A Convertible Cumulative Preferred Stock, Par Value $0.00001 Per Share,
IntelGenx Launches Preferred Share Regulation A Offering
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx's VetaFilm Platform
IntelGenx Announces New Animal Health Partnership; Enters Into Development and License Agreements for VetaFilm
SAINT LAURENT, Quebec, Dec. 18, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has entered into development and license agreements
IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With Atai Life Sciences for Aggregate Gross Proceeds of US$750,000
IntelGenx Announces Changes to Its Board of Directors
IntelGenx Announces Shareholder Approval of Financing Transactions
SAINT LAURENT, Quebec, Nov. 28, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) ("IntelGenx" or the "Company") is pleased to announce that, at its meeting held earlier today (the "Special
IntelGenx Receives Approval to Conduct 'MONTPARK' Montelukast VersaFilm Phase 2 Clinical Trial in Patients With Parkinson's Disease
SAINT LAURENT, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that the Swedish Medical Products Agency ("MPA"), the
No Data